Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Papillomavirus Infections 4Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 3Pancreatic Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Follicular 3Triple Negative Breast Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Waldenstrom Macroglobulinemia 1Thymic aplasia 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pneumonia 1Osteosarcoma 1Obesity 1Neurofibromatosis 1 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphohistiocytosis, Hemophagocytic 1

Interventions

letermovir 1Valganciclovir 1Valacyclovir 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytomegalovirus Infections × Blood Specimen Collection × Clear all
NCT04017962 2025-08-11

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 13 charts

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡